MedTrace Logo

Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy

NCT00746395 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2020-10-08

Study results available
· View outcomes & findings →

Summary

This investigation is designed to compare lubiprostone and placebo for cleansing and propulsion in preparation for capsule endoscopy.

Conditions

Interventions

DRUG

Lubiprostone

24 mcg oral administration

DRUG

Placebo

Oral administration

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • Sucampo Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • University of South Alabama

    lead OTHER

Principal Investigators

  • JAck A DiPalma, MD · University of South Alabama

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00746395 on ClinicalTrials.gov